- cafead Mar 05, 2024 at 11:22: AM
via After more than two years in the doldrums, initial public offerings, an important indicator of the biotechnology industry’s health, have shown signs of life.
A run of offerings in the first six weeks of 2024, most worth around $100 million or more, has put the sector on its strongest pace since 2021. Those IPOs, combined with the recovery of biotech’s two flagship stock funds and a dealmaking surge, have given industry watchers reasons to be optimistic.
article source
A run of offerings in the first six weeks of 2024, most worth around $100 million or more, has put the sector on its strongest pace since 2021. Those IPOs, combined with the recovery of biotech’s two flagship stock funds and a dealmaking surge, have given industry watchers reasons to be optimistic.
article source